Dobutamine and gastric-to-arterial carbon dioxide gap in severe sepsis without shock

Intensive Care Med. 2002 Mar;28(3):265-71. doi: 10.1007/s00134-001-1198-x. Epub 2002 Feb 8.

Abstract

Objectives: To evaluate the effect of an early dobutamine infusion on gastrointestinal perfusion in patients with severe sepsis.

Design: Prospective, randomized, controlled, multicenter clinical study.

Setting: Six medical and/or surgical intensive care units (ICU) of teaching hospitals.

Patients: Forty-two patients with severe sepsis.

Interventions: Patients were divided into two groups according to gastric-to-arterial CO2 gap (DeltaCO2) [normal DeltaCO2 group ( n=17): DeltaCO2 < or = 8 mmHg; increased DeltaCO2 group ( n=25): DeltaCO2 > 8 mmHg]. Patients within each group were then randomized to receive either dobutamine (5 microg/kg per min) or saline for 72 h.

Measurements and main results: SAPS II was similar in both groups [group 1: 44.0 (33.0-56.5); group 2: 48.5 (40.5-59.0), p=0.27]. At ICU admission, mean arterial pressure was lower in the high DeltaCO2 group [73.0 (67.0-79.5) mmHg, p=0.03] than in the normal DeltaCO2 group [84.0 (73.7-104.0) mmHg] while blood lactate [normal DeltaCO2 group: 1.6 (0.8-2.3); high DeltaCO2 group: 1.6 (1.1-1.9) mmol/l] was similar for the two groups. DeltaCO2 was significantly lower in the normal DeltaCO2 group [5.0 (2.0-6.0) mmHg)] than in the high DeltaCO2 group [11.0 (10.0-19.0) mmHg]. Dobutamine infusion did not significantly change hemodynamics, blood lactate concentration or tonometric parameters in any group within the first 72 h and had no particular beneficial effect in this population.

Conclusions: An early infusion of dobutamine at a fixed dose of 5 microg/kg per min during the first 72 h of severe sepsis does not influence gastric DeltaCO2.

Publication types

  • Clinical Trial
  • Multicenter Study
  • Randomized Controlled Trial

MeSH terms

  • APACHE
  • Aged
  • Carbon Dioxide / blood*
  • Carbon Dioxide / metabolism
  • Cardiotonic Agents / therapeutic use*
  • Digestive System / metabolism*
  • Dobutamine / therapeutic use*
  • Female
  • Hemodynamics / drug effects*
  • Humans
  • Infusions, Intravenous
  • Lactates / blood
  • Length of Stay
  • Male
  • Middle Aged
  • Multiple Organ Failure / etiology
  • Multiple Organ Failure / mortality
  • Sepsis / classification
  • Sepsis / complications
  • Sepsis / drug therapy*
  • Treatment Outcome

Substances

  • Cardiotonic Agents
  • Lactates
  • Carbon Dioxide
  • Dobutamine